In peritoneal macrophage cultures, Iwamoto et al. observed that tofogliflozin modulated hyperglycemia by inhibiting macrophage accumulation and downregulating IL-1β and IL-6 expression, resulting in a significant reduction in atherosclerotic plaque burden. Here, IL6 is linked to Hyperglycemia.